Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Growth in Short Interest

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) was the recipient of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 15,900 shares, a growth of 37.1% from the November 15th total of 11,600 shares. Currently, 0.4% of the company's stock are sold short. Based on an average daily volume of 33,200 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Jefferies Financial Group raised shares of Assembly Biosciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $2.00 to $35.00 in a research report on Friday, September 20th. HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Tuesday, September 24th.

Insider Activity

In other news, major shareholder Alexander Schornstein acquired 10,000 shares of Assembly Biosciences stock in a transaction on Tuesday, October 8th. The stock was purchased at an average price of $14.58 per share, with a total value of $145,800.00. Following the completion of the purchase, the insider now owns 703,113 shares of the company's stock, valued at approximately $10,251,387.54. The trade was a 1.44 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 394 shares of company stock worth $5,894. Company insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of ASMB. FMR LLC grew its stake in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock worth $240,000 after acquiring an additional 3,635 shares in the last quarter. Armistice Capital LLC bought a new stake in Assembly Biosciences in the 2nd quarter worth about $6,421,000. Renaissance Technologies LLC increased its stake in Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company's stock valued at $753,000 after buying an additional 15,451 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company's stock worth $184,000 after buying an additional 7,690 shares in the last quarter. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Stock Performance

Shares of Assembly Biosciences stock traded up $0.03 on Friday, hitting $15.38. The company had a trading volume of 10,278 shares, compared to its average volume of 24,476. Assembly Biosciences has a 1 year low of $8.82 and a 1 year high of $19.93. The stock has a 50 day moving average of $16.42 and a 200-day moving average of $15.59.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.